Search results
Results From The WOW.Com Content Network
Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
Teva's generic launch comes days after the U.S. Food and Drug Administration tentatively approved London-based Hikma Pharmaceuticals' generic version of Victoza, according to the agency's website.
It is also approved in Canada and Australia. As of 2023, it remained unapproved for any use in the United States, [11] although Hikma Pharmaceuticals had agreed in 2021 to begin the FDA approval process. [12] Evidence has shown that bilastine is effective in treating skin and eye symptoms of allergic reactions, improving patient's quality of life.
Baxter acquired medical device firm Baxa on November 10, 2011. [18] In 2011, Hikma Pharmaceuticals PLC completed the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI). [19] [20] In July 2013, EU antitrust regulators approved Baxter's bid for Sweden's Gambro. [21]
Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
BTG Limited is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. [2]
Liraglutide was approved for medical use in the European Union in 2009, [4] and in the United States in 2010. [11] It is available as a generic medication. [12] In 2022, it was the 139th most commonly prescribed medication in the United States, with more than 4 million prescriptions. [13] [14]